Cargando…

Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer’s disease

BACKGROUND: Alzheimer’s disease (AD) causes substantial medical and societal burden with no therapies ameliorating cognitive deficits. Centralized pathologies involving amyloids, neurofibrillary tangles, and neuroinflammatory pathways are being investigated to identify disease-modifying targets for...

Descripción completa

Detalles Bibliográficos
Autores principales: Banik, Avijit, Amaradhi, Radhika, Lee, Daniel, Sau, Michael, Wang, Wenyi, Dingledine, Raymond, Ganesh, Thota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605573/
https://www.ncbi.nlm.nih.gov/pubmed/34801055
http://dx.doi.org/10.1186/s12974-021-02297-7
_version_ 1784602209122516992
author Banik, Avijit
Amaradhi, Radhika
Lee, Daniel
Sau, Michael
Wang, Wenyi
Dingledine, Raymond
Ganesh, Thota
author_facet Banik, Avijit
Amaradhi, Radhika
Lee, Daniel
Sau, Michael
Wang, Wenyi
Dingledine, Raymond
Ganesh, Thota
author_sort Banik, Avijit
collection PubMed
description BACKGROUND: Alzheimer’s disease (AD) causes substantial medical and societal burden with no therapies ameliorating cognitive deficits. Centralized pathologies involving amyloids, neurofibrillary tangles, and neuroinflammatory pathways are being investigated to identify disease-modifying targets for AD. Cyclooxygenase-2 (COX-2) is one of the potential neuroinflammatory agents involved in AD progression. However, chronic use of COX-2 inhibitors in patients produced adverse cardiovascular effects. We asked whether inhibition of EP2 receptors, downstream of the COX-2 signaling pathway, can ameliorate neuroinflammation in AD brains in presence or absence of a secondary inflammatory stimuli. METHODS: We treated 5xFAD mice and their non-transgenic (nTg) littermates in presence or absence of lipopolysaccharide (LPS) with an EP2 antagonist (TG11-77.HCl). In cohort 1, nTg (no-hit) or 5xFAD (single-hit—genetic) mice were treated with vehicle or TG11-77.HCl for 12 weeks. In cohort 2, nTg (single-hit—environmental) and 5xFAD mice (two-hit) were administered LPS (0.5 mg/kg/week) and treated with vehicle or TG11-77.HCl for 8 weeks. RESULTS: Complete blood count analysis showed that LPS induced anemia of inflammation in both groups in cohort 2. There was no adverse effect of LPS or EP2 antagonist on body weight throughout the treatment. In the neocortex isolated from the two-hit cohort of females, but not males, the elevated mRNA levels of proinflammatory mediators (IL-1β, TNF, IL-6, CCL2, EP2), glial markers (IBA1, GFAP, CD11b, S110B), and glial proteins were significantly reduced by EP2 antagonist treatment. Intriguingly, the EP2 antagonist had no effect on either of the single-hit cohorts. There was a modest increase in amyloid–plaque deposition upon EP2 antagonist treatment in the two-hit female brains, but not in the single-hit genetic female cohort. CONCLUSION: These results reveal a potential neuroinflammatory role for EP2 in the two-hit 5xFAD mouse model. A selective EP2 antagonist reduces inflammation only in female AD mice subjected to a second inflammatory insult. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-021-02297-7.
format Online
Article
Text
id pubmed-8605573
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86055732021-11-22 Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer’s disease Banik, Avijit Amaradhi, Radhika Lee, Daniel Sau, Michael Wang, Wenyi Dingledine, Raymond Ganesh, Thota J Neuroinflammation Research BACKGROUND: Alzheimer’s disease (AD) causes substantial medical and societal burden with no therapies ameliorating cognitive deficits. Centralized pathologies involving amyloids, neurofibrillary tangles, and neuroinflammatory pathways are being investigated to identify disease-modifying targets for AD. Cyclooxygenase-2 (COX-2) is one of the potential neuroinflammatory agents involved in AD progression. However, chronic use of COX-2 inhibitors in patients produced adverse cardiovascular effects. We asked whether inhibition of EP2 receptors, downstream of the COX-2 signaling pathway, can ameliorate neuroinflammation in AD brains in presence or absence of a secondary inflammatory stimuli. METHODS: We treated 5xFAD mice and their non-transgenic (nTg) littermates in presence or absence of lipopolysaccharide (LPS) with an EP2 antagonist (TG11-77.HCl). In cohort 1, nTg (no-hit) or 5xFAD (single-hit—genetic) mice were treated with vehicle or TG11-77.HCl for 12 weeks. In cohort 2, nTg (single-hit—environmental) and 5xFAD mice (two-hit) were administered LPS (0.5 mg/kg/week) and treated with vehicle or TG11-77.HCl for 8 weeks. RESULTS: Complete blood count analysis showed that LPS induced anemia of inflammation in both groups in cohort 2. There was no adverse effect of LPS or EP2 antagonist on body weight throughout the treatment. In the neocortex isolated from the two-hit cohort of females, but not males, the elevated mRNA levels of proinflammatory mediators (IL-1β, TNF, IL-6, CCL2, EP2), glial markers (IBA1, GFAP, CD11b, S110B), and glial proteins were significantly reduced by EP2 antagonist treatment. Intriguingly, the EP2 antagonist had no effect on either of the single-hit cohorts. There was a modest increase in amyloid–plaque deposition upon EP2 antagonist treatment in the two-hit female brains, but not in the single-hit genetic female cohort. CONCLUSION: These results reveal a potential neuroinflammatory role for EP2 in the two-hit 5xFAD mouse model. A selective EP2 antagonist reduces inflammation only in female AD mice subjected to a second inflammatory insult. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-021-02297-7. BioMed Central 2021-11-20 /pmc/articles/PMC8605573/ /pubmed/34801055 http://dx.doi.org/10.1186/s12974-021-02297-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Banik, Avijit
Amaradhi, Radhika
Lee, Daniel
Sau, Michael
Wang, Wenyi
Dingledine, Raymond
Ganesh, Thota
Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer’s disease
title Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer’s disease
title_full Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer’s disease
title_fullStr Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer’s disease
title_full_unstemmed Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer’s disease
title_short Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer’s disease
title_sort prostaglandin ep2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605573/
https://www.ncbi.nlm.nih.gov/pubmed/34801055
http://dx.doi.org/10.1186/s12974-021-02297-7
work_keys_str_mv AT banikavijit prostaglandinep2receptorantagonistamelioratesneuroinflammationinatwohitmousemodelofalzheimersdisease
AT amaradhiradhika prostaglandinep2receptorantagonistamelioratesneuroinflammationinatwohitmousemodelofalzheimersdisease
AT leedaniel prostaglandinep2receptorantagonistamelioratesneuroinflammationinatwohitmousemodelofalzheimersdisease
AT saumichael prostaglandinep2receptorantagonistamelioratesneuroinflammationinatwohitmousemodelofalzheimersdisease
AT wangwenyi prostaglandinep2receptorantagonistamelioratesneuroinflammationinatwohitmousemodelofalzheimersdisease
AT dingledineraymond prostaglandinep2receptorantagonistamelioratesneuroinflammationinatwohitmousemodelofalzheimersdisease
AT ganeshthota prostaglandinep2receptorantagonistamelioratesneuroinflammationinatwohitmousemodelofalzheimersdisease